デフォルト表紙
市場調査レポート
商品コード
1008135

悪性黒色腫市場(2020年~2026年)

Melanoma Cancer Market 2020-2026

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円
悪性黒色腫市場(2020年~2026年)
出版日: 2021年05月05日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の悪性黒色腫市場は、予測期間中に約12.3%のCAGRで大幅に拡大すると予測されています。世界における悪性黒色腫の発生率の増加は、同市場の成長を後押しする主な要因です。治療のための免疫療法と標的療法薬の採用の増加、治療を強化するための技術の進歩、治療と診断についての意識の高まりも市場の成長を後押ししています。

また、新薬や治療法の研究開発に対する政府の資金援助と、食品医薬品局による規制当局の承認数の増加により、予測期間中に市場が牽引されると予想されています。ただし、治療に関連する高コスト、ジェネリック医薬品の使用の増加などの特定の要因は、市場成長の妨げとなっています。一方、医薬品開発の革新、およびその後の技術の進歩とパイプライン製品は、同市場の大きな機会として期待されています。

当レポートは、世界の悪性黒色腫市場について調査しており、市場規模や予測、成長および抑制要因、機会、診断・治療・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
  • 規則

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • 主要戦略分析

第4章 市場の決定要因

  • 成長要因
  • 抑制要因
  • 市場機会

第5章 市場セグメンテーション

  • 診断別
    • 生検
    • コンピュータ断層撮影(CT)スキャン
    • 磁気共鳴画像法(MRI)
    • その他(PET)
  • 治療別
    • 化学療法
    • 免疫療法
    • 標的療法
    • 放射線治療

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他
  • その他の地域

第7章 企業プロファイル

  • Abbott Laboratories
  • Ab Sciences
  • AbbVie Inc.
  • Amgen, Inc.
  • AstraZeneca plc
  • Bristol-Myers Squibb Co.
  • Castle Biosciences, Inc.
  • Celgene Corp.
  • Chinook Therapeutics, Inc.
  • Daiichi Sankyo Co., Ltd.
  • ENB Therapeutics
  • Eisai Co Ltd.
  • F. Hoffman-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Incyte Corp.
  • Iovance Biotherapeutics Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pierre Fabre S. A.
  • SciBase AB
図表

LIST OF TABLES

  • 1. GLOBAL MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 2. GLOBAL BIOPSY FOR MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 3. GLOBAL COMPUTED TOMOGRAPHY (CT) SCAN FOR MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) FOR MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 5. GLOBAL POSITRON OTHER DIAGNOSIS FOR MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 6. GLOBAL MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027($ MILLION)
  • 7. GLOBAL CHEMOTHERAPYFOR MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 8. GLOBAL IMMUNOTHERAPYFOR MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 9. GLOBAL TARGETED THERAPYFOR MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 10. GLOBAL RADIATION THERAPYFOR MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 11. GLOBAL MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027($ MILLION)
  • 12. NORTH AMERICAN MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 13. NORTH AMERICAN MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027($ MILLION)
  • 14. NORTH AMERICAN MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BYDIAGNOSIS, 2020-2027($ MILLION)
  • 15. EUROPEAN MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 16. EUROPEAN MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY,2020-2027($ MILLION)
  • 17. EUROPEAN MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS,2020-2027($ MILLION)
  • 18. ASIA-PACIFIC MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 19. ASIA-PACIFIC MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY,2020-2027($ MILLION)
  • 20. ASIA-PACIFIC MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS,2020-2027($ MILLION)
  • 21. REST OF THE WORLD MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 22. REST OF THE WORLD MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY,2020-2027($ MILLION)
  • 23. REST OF THE WORLD MELANOMA CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS,2020-2027($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL MELANOMA CANCER MARKET SHARE BY THERAPY, 2020 VS 2027 (%)
  • 2. GLOBAL MELANOMA CANCER MARKET SHARE BY DIAGNOSIS METHOD, 2020 VS 2027 (%)
  • 3. GLOBAL CHEMOTHERAPY FOR MELANOMA CANCER SHARE BY REGION, 2020 VS 2027 (%)
  • 4. GLOBAL IMMUNOTHERAPY FOR MELANOMA CANCER SHARE BY REGION, 2020 VS 2027 (%)
  • 5. GLOBAL TARGETED THERAPY FOR MELANOMA CANCER SHARE BY REGION, 2020 VS 2027 (%)
  • 6. GLOBAL RADIATION THERAPY FOR MELANOMA CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 7. GLOBAL BIOPSY FOR MELANOMA CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 8. GLOBAL COMPUTED TOMOGRAPHY (CAT) SCAN FOR MELANOMA CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 9. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) FOR MELANOMA CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL OTHER DIAGNOSIS FOR MELANOMA CANCER MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL MELANOMA CANCER MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. US MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION)
  • 13. CANADA MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION)
  • 14. UK MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION)
  • 15. FRANCE MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION)
  • 16. GERMANY MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION)
  • 17. ITALY MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION)
  • 18. SPAIN MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION)
  • 19. REST OF EUROPE MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION)
  • 20. INDIA MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION)
  • 21. CHINA MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION)
  • 22. JAPAN MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION)
  • 23. REST OF ASIA-PACIFIC MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION)

24. REST OF THE WORLD MELANOMA CANCER MARKET SIZE, 2020-2027($ MILLION

目次
Product Code: OMR2023428

Global Melanoma Cancer Market Size, Share & Trends Analysis Report By Diagnosis (Biopsy, Computed Tomography (CAT) Scan, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) Scan), By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Radiation therapy), Forecast 2021-2027

The global market for melanoma cancer is projected to have a considerable CAGR of around 12.3% during the forecast period. Melanoma is a skin cancer that develops in the melanocyte cells, responsible for producing melanin, a pigment that gives color to the skin. It is the most serious type of skin cancer and it seems to be increasing in people under 40, especially women. The disease is curable when recognized and treated in the early stages and hence has a high success rate. The increasing incidence of melanoma skin cancer across the globe is the major factor boosting the growth of the market. For instance, according to the report of the American Academy of Dermatology Association, approximately 9,500 people in the US are diagnosed with skin cancer every day. More than 1 million Americans are living with melanoma. Melanoma is the second most common form of cancer in females age 15-29. The increasing adoption of immunotherapy and targeted therapy drugs for skin treatments, technological advancement to enhance the treatment, rising awareness about the treatment and diagnosis also drive the market growth. The government funding support for R&D of new drugs and therapies and the increasing number of regulatory approvals by the Food and Drug Administration anticipated driving the market during the forecast period.

However, certain factors such as high costs associated with treatment, and increasing use of generic medicine are hindering the growth of the market. Medicines such as cisplatin is a generic and off-patent drug and are manufactured by multiple companies for cancer treatment across the globe. Innovation in drug development, and subsequent technological advancements & pipeline products are expected to create significant opportunities for the melanoma cancer market.

Segmental Outlook

The global melanoma market is segmented based on diagnosis and therapy. Based on therapy, the market is segmented into immunotherapy, targeted therapy, chemotherapy, and radiation therapy. On the basis of diagnosis, the market is further segmented into biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), and positron emission tomography (PET) scan. Among these diagnosis methods, CT scan is projected to have a significant market share during the forecast period. A computerized tomography scan (CT or CAT scan) uses computers and rotating X-ray machines to create cross-sectional images of the body. Thus, the rising prevalence of melanoma will increase the demand for this, which, in turn, will further drive the growth of the market.

Global Melanoma Cancer Market Share by Therapy, 2020(%)

Source: OMR Global

Immunotherapy is projected to have a significant share in the melanoma cancer market.

Among therapy, immunotherapy holds the major market share in 2020 and is anticipated to grow at a significant CAGR during the forecast period. Immunotherapy is the use of medicines to stimulate a person's immune system to recognize and destroy cancer cells more effectively. Immunotherapies are considered best for the treatment of melanoma, owing to the fewer adverse effects than other therapies, and provide longer life by boosting the immune system. The US Food and Drug Association have approved immunotherapy drugs for melanoma cancer which includes Ipilimumab (Yervoy), which is an anti-CTLA-4 inhibitor, Pembrolizumab (Keytruda), Nivolumab (Opdivo), Interleukin-2 (IL-2, Aldesleukin(PROLEUKIN). However, targeted therapy is expected to have considerable growth during the forecast period. Targeted therapies target parts of melanoma cells, these medicines work on genes and proteins in melanoma cells. The targeted therapy uses BRAF inhibitors which includes Zelboraf (vemurafenib) and Tafinlar (dabrafenib) drugs that target the BRAF gene. BRAF is a gene that's part of body cells. Moreover, targeted therapies are growing in the field of cancer research.

Regional Outlook

Geographically, the global melanoma cancer market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia-Pacific (India, China, Japan, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Asia-Pacific is expected to have considerable market growth during the forecast period owing to key contributions from China, Australia, Japan, and India. A massive pool of patients, rising disposable income, and an improving healthcare system are the major factors for the growth of the market in the region. Apart from this, the government support for R&D in technology for better skin cancer treatments, and low drug production cost is the crucial factors driving the growth of the market in the region.

Global Melanoma Cancer Market Growth, by Region 2021-2027

Source: OMR Global

North America is anticipated to dominate the global melanoma cancer market.

Geographically, North America is projected to dominate the global melanoma market owing to the high prevalence of melanoma in the US and Canada along with a major market share in the region. Well-developed healthcare infrastructure and reimbursement policies are some of the major factors that are contributing to the growth of the market in the region. The presence of major market players and initiatives take by them to generate more revenue by producing new drugs also impact positively on the growth of the market. Europe is also expected to have a significant market share during the forecast period due to the increasing number of skin cancer cases, and the development of novel drugs. The UK, Germany, and France are the major countries with a high prevalence of melanoma cancer and contribute significantly to the market.

Market Players Outlook

The key players in the melanoma cancer market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are Bristol-Myers Squibb Co., GlaxoSmithKline plc, AstraZeneca PLC, Amgen Inc, Novartis AG, Abbott Laboratories, Johnson & Johnson Services, Inc., and others. To sustain a strong position in the market, these market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, and geographical expansions so on. For instance, in March 2021, Castle Biosciences, Inc has recently launched DecisionDx-Melanoma Integrated Test. It is Castle's prognostic gene expression profile test for cutaneous melanoma. Furthermore, The Company expects to launch an app in 2021 featuring interactive algorithms using the integrated GEP score and traditional clinicopathologic factors to predict risk.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global melanoma cancer market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Melanoma Cancer Market, ByDiagnosis
    • 5.1.1. Biopsy
    • 5.1.2. Computed Tomography (CT) Scan
    • 5.1.3. Magnetic Resonance Imaging (MRI)
    • 5.1.4. Others (PET)
  • 5.2. Global Melanoma Cancer Market, By Therapy
    • 5.2.1. Chemotherapy
    • 5.2.2. Immunotherapy
    • 5.2.3. Targeted Therapy
    • 5.2.4. Radiation Therapy

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Ab Sciences
  • 7.3. AbbVie Inc.
  • 7.4. Amgen, Inc.
  • 7.5. AstraZeneca plc
  • 7.6. Bristol-Myers Squibb Co.
  • 7.7. Castle Biosciences, Inc.
  • 7.8. Celgene Corp.
  • 7.9. Chinook Therapeutics, Inc.
  • 7.10. Daiichi Sankyo Co., Ltd.
  • 7.11. ENB Therapeutics
  • 7.12. Eisai Co Ltd.
  • 7.13. F. Hoffman-La Roche Ltd.
  • 7.14. GlaxoSmithKline PLC
  • 7.15. Incyte Corp.
  • 7.16. Iovance Biotherapeutics Inc.
  • 7.17. Johnson & Johnson Services, Inc.
  • 7.18. Merck & Co., Inc.
  • 7.19. Novartis AG
  • 7.20. Pierre Fabre S. A.
  • 7.21. SciBase AB